Alzheimer's clinical studies what can you do ?

One of the most important worldwide challenges are the next generation Alzheimer's disease treatments. Alzheimer's disease treatments worldwide leaders will meet at the CTAD 2019 Congress in order to discuss new results, candidate therapeutics, and methodological issues. Alzheimer's disease symptoms and dementia treatment will be dealt with at the CTAD 2019 Congress. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. The importance of non-pharmaceutical trials and that anti-amyloid treatment for AD was shown at the 2018 CTAD Congress. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. New examples of trials will be highlighted in the 2019 CTAD Congress. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments. Reviews, original research articles and short reports on Alzheimer prevention will be published in the JPAD . They will include articles on the following topics : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.